The 68th American Society of Hematology (ASH) Annual Meeting will take place December 12–15, 2026, in New Orleans, United States. As one of the most influential annual academic gatherings in hematology worldwide, ASH brings together specialists and researchers from across the globe to present the latest advances in basic research, clinical diagnosis and treatment, and innovative therapy for blood disorders, and to discuss where the field is heading and what the next therapeutic opportunities will be.
At this year's meeting, GOBROAD Medical Group has 25 studies accepted: 4 oral presentations, 12 posters, and 9 online publications. The accepted work spans CAR-T cell therapy, hematopoietic stem cell transplantation, precision diagnosis and treatment of hematologic malignancies, and post-transplant complication management. It addresses both the continued refinement of innovative treatment strategies and the hard clinical problems of relapsed and refractory disease, treatment resistance, transplant risk, and long-term survival — a picture of sustained depth across both clinical care and research.
Oral Presentations
Early Consolidative HSCT Promotes CD7+ T-cell Recovery and Improves Survival After CD7 CAR-T-cell Therapy for R/R T-ALL: A 206-Patient Multicohort Analysis
Abstract: 446
Presenter: Zhang Min
Corresponding Author: Pan Jing
Affiliation: Chinese Institutes for Medical Research; Beijing GOBROAD Hospital, GOBROAD Medical Group
Addition of Cyclophosphamide on Day -1 Significantly Reduces Graft Rejection in TCRαβ+ Depleted Haplo-HCT for Thalassemia Major
Abstract: 636
Presenter: Liao Jianyun
Corresponding Author: Li Chunfu
Affiliation: GOBROAD Chunfu Hematology Research Institute, GOBROAD Medical Group
Clinical Activity and Pharmacodynamic Evidence of CD19 CAR T-cell Therapy in Relapsed/Refractory Idiopathic Multicentric Castleman Disease: An Expanded Case Series
Abstract: 869
Presenter and First Author: Zhang Yajing
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Viral Infections and Reactivations Following CAR-T Cell Therapy and Their Impact on Survival Outcomes in B-cell Non-Hodgkin Lymphoma: A Real-World Study of 641 Patients
Abstract: 1094
Presenter: Cao Miaomiao
Corresponding Author: Hu Kai, Ke Xiaoyan
Affiliation: Beijing GOBROAD Hospital, GOBROAD Medical Group
Poster Presentations
Sequential Consolidation Strategies After CAR-T Cell Therapy Are Associated With Durable Disease Control in Adults With Relapsed/Refractory Burkitt Lymphoma
Abstract: 1926
First Author: Ma Lixia
Corresponding Author: Hu Kai, Ke Xiaoyan
Affiliation: Beijing GOBROAD Hospital, GOBROAD Medical Group
6–7 Day CART19 Cell Products Have Good Characteristics for Clinical Application
Abstract: 2423
First Author: Deng Biping
Corresponding Author: Tong Chunrong
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
CD7 CAR-T Therapy Bridged to Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Patients With Refractory/Relapsed T-ALL/LBL
Abstract: 2492
First Author: Fang Fang
Corresponding Author: Zhao Yongqiang, Wu Tong
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Integrated Clinical and Genomic Risk Stratification Identifies Patients Most Likely to Benefit From Second Allogeneic Hematopoietic Cell Transplantation
Abstract: 2511
First Author: Li Zhihui
Corresponding Author: Wu Tong
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Integrative Genetic and Transcriptomic Analyses Distinguish MYC-Rearranged B-cell Precursor Acute Lymphoblastic Leukemia/Lymphoma From Burkitt Lymphoma/Leukemia
Abstract: 3331
First Author: Xia Xiayu
Corresponding Author: Zheng Qinlong
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Characteristics and Clinical Prognostic Impact of ZNF384-Fusion Variants in Leukemia
Abstract: 3335
First Author: Yang Keyan
Corresponding Author: Zheng Qinlong
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Impact of Histologic Transformation and POD24 on Outcomes After CAR T-cell Therapy in Follicular Lymphoma: A Real-World Study
Abstract: 3536
First Author: Liu Rui
Corresponding Author: Hu Kai, Ke Xiaoyan
Affiliation: Beijing GOBROAD Hospital, GOBROAD Medical Group
Clinical Manifestation-Driven Stratification of Belumosudil in Pediatric Chronic Graft-Versus-Host Disease: Best Overall Response and Immunosuppression Discontinuation in 61 Children
Abstract: 4234
First Author: Liao Jianyun
Corresponding Author: Li Chunfu
Affiliation: GOBROAD Chunfu Hematology Research Institute, GOBROAD Medical Group
Clinical Significance of UBA1 Mutations in a Large Myeloid NGS Cohort: Diagnostic Utility Across Variant Allele Frequencies and Distinct Features in Female Patients
Abstract: 4899
Authors: Rong He (first author), Li Zhihui (co-author), David Viswanatha (corresponding author), and 24 additional collaborating investigators
Affiliation: Mayo Clinic; Beijing GOBROAD Boren Hospital, GOBROAD Medical Group; University of Utah; University of Michigan; and other collaborating institutions
Rescue Strategies for Early Poor CAR-T Cell Expansion: Investigating the Role of Immunomodulators and PD-1 Inhibitors in Patients With Relapsed/Refractory LBCL
Abstract: 5453
First Author: Yang Fan
Corresponding Author: Hu Kai, Ke Xiaoyan
Affiliation: Beijing GOBROAD Hospital, GOBROAD Medical Group
Rapid Viral Clearance and T-cell Reconstitution in Refractory Multi-Viral Infections After Allogeneic Hematopoietic Cell Transplantation With Donor-Derived CD45RO+ Memory T-cell Infusion: A Matched-Control Study
Abstract: 5999
First Author: Li Zhihui
Corresponding Author: Wu Tong
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Multiline Sequential Therapies for Relapsed/Refractory Secondary CNS Lymphoma in the Immunotherapy Era: A Single-Center Retrospective Study of 60 Patients
Abstract: 6262
First Author: Yang Fan
Corresponding Author: Hu Kai, Ke Xiaoyan
Affiliation: Beijing GOBROAD Hospital, GOBROAD Medical Group
Online Publications
A Novel TSC1::FGFR1 Fusion Drives Clonal Evolution and Resistance in BCR::ABL1-Positive B-ALL
Abstract: 7047
First Author: Jia Xiaopeng
Corresponding Author: Yan Ju, Lin Yuehui
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Germline Mutation Profiling and Its Impact on Prognosis in Chinese Pediatric Mature B-cell Non-Hodgkin Lymphoma
Abstract: 7295
First Author: Li Yang, Duan Yanlong
Corresponding Author: Zheng Qinlong, Zhang Yonghong
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group; Beijing Children's Hospital, Capital Medical University, and 13 hospitals of the CNCL collaborative group
Dynamic Immune Profiling Predicts Long-Term Efficacy in Patients With Diffuse Large B-cell Lymphoma Following CD19 CAR-T Cell Therapy: Development of Baseline and Post-Infusion Predictive Models
Abstract: 7321
First Author: Yang Fan
Corresponding Author: Hu Kai, Ke Xiaoyan
Affiliation: Beijing GOBROAD Hospital, GOBROAD Medical Group
Chidamide and Azacitidine-Based miniMINE or CPET Regimens With or Without Targeted Agents for Relapsed/Refractory Angioimmunoblastic T-cell Lymphoma: A Real-World Retrospective Study
Abstract: 7449
First Author: Guo Yuelu
Corresponding Author: Hu Kai, Ke Xiaoyan
Affiliation: Beijing GOBROAD Hospital, GOBROAD Medical Group
Combined Baseline Lymphocyte-to-Monocyte Ratio and Platelet-to-Lymphocyte Ratio Predict Survival Outcomes in Patients With Relapsed/Refractory B-cell Lymphoma Treated With CAR-T Cell Therapy
Abstract: 7557
First Author: Zhang Na
Corresponding Author: Hu Kai, Ke Xiaoyan
Affiliation: Beijing GOBROAD Hospital, GOBROAD Medical Group
Real-World Outcomes in Ultra-High-Risk, Heavily Pretreated Relapsed/Refractory Multiple Myeloma: A Single-Center Experience
Abstract: 8004
First Author: Cheng Fangfang
Corresponding Author: Zhang Yajing
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Beyond Conventional Eligibility: Vulnerability-Adapted CAR T-cell Therapy for Multiple Myeloma in the Setting of Advanced Age, Treatment Intolerance, or Severe Organ Dysfunction
Abstract: 8032
First Author: Han Xuelin
Corresponding Author: Zhang Yajing
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Beyond Deep Marrow Response: Lesion-Resolved Single-Cell Profiling of Extramedullary Progression After Sequential Immunotherapies in Multiple Myeloma
Abstract: 8105
First Author: He Ruijie
Corresponding Author: Zhang Yajing
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
Transitional Continuous Nursing and Complication Management for Patients Undergoing Second Allo-HSCT Bridged With CAR-T Therapy
Abstract: 8477
First Author: Wang Xiaoxia
Corresponding Author: Wu Tong
Affiliation: Beijing GOBROAD Boren Hospital, GOBROAD Medical Group
The value of clinical exploration lies not only in accumulating new evidence, but in letting different experiences and ways of thinking illuminate one another. ASH 2026 brings together the collective wisdom of the global hematology community and gives GOBROAD Medical Group a broad stage on which to share research findings and exchange clinical insight with international peers. Different clinical experiences inspire one another in conversation, diverse academic perspectives open new possibilities through mutual learning, and every step of medical innovation remains closely tied to real clinical need.
Starting from clinical need and ending with patient benefit, GOBROAD Medical Group will continue to focus on the unresolved problems in the diagnosis and treatment of hematologic disease, to drive deep integration of clinical care, scientific research, and translational innovation, and to shorten the distance between discovery and application through sustained exploration and open collaboration — so that more innovations become genuinely accessible treatment options, and more patients worldwide with blood disorders gain longer survival and a better quality of life.
This article is a press summary based on accepted conference abstracts and is intended for general informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Please consult a qualified physician for any medical decision.